Assessment of a lupus nephritis cohort over a 30-year period

被引:140
作者
Croca, Sara C. [1 ]
Rodrigues, Teresa [2 ]
Isenberg, David A. [3 ]
机构
[1] Hosp Santa Maria, Serv Med 1, Dept Internal Med 1, P-1649035 Lisbon, Portugal
[2] Fac Med Lisbon, Dept Biomath, Lisbon, Portugal
[3] UCL, Dept Med, Ctr Rheumatol, London, England
关键词
Lupus nephritis; 30-year assessment; Mortality; End-stage renal disease; MEMBRANOUS NEPHROPATHY; RETROSPECTIVE ANALYSIS; CONTROLLED-TRIAL; ERYTHEMATOSUS; AUTOANTIBODIES; ANTIBODIES; DISEASE; CYCLOPHOSPHAMIDE; ASSOCIATIONS; PROGNOSIS;
D O I
10.1093/rheumatology/ker101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Methods. Between 1975 and 2005, 156 LN patients were followed up at University College Hospital London. We divided them into three groups depending on the date of recognition of renal involvement (1975-85, 1986-95 and 1996-2005) and compared them in terms of clinical, demographic and serological characteristics and disease outcome. Results. Clinical characteristics were comparable between groups; however, the proportion of Afro-caribbean (AC) patients and the prevalence of anti-ENA antibodies rose significantly over time. The 5-year mortality rate decreased by 60% between the first and second decades, remaining stable over the third decade. The 5-year end-stage renal disease (ESRD) rate remained constant. An increasing number of renal transplants (RTx) was performed with encouraging results. AC origin was associated with a poorer overall prognosis. Conclusion. LN, a common complication of SLE, is associated with increased mortality and morbidity, particularly among AC patients. Despite encouraging results for RTx, once ESRD is established the prognosis is relatively poor and no improvement in preventing its development was achieved. Moreover, although a significant decrease in mortality was observed, it has remained stable for 10 years. These results suggest that we have maximized the benefits of conventional therapies and if further improvement is to be achieved, novel drug regimens must be developed.
引用
收藏
页码:1424 / 1430
页数:7
相关论文
共 34 条
[1]  
ADLER M, 2006, RHEUMATOLOGY, P54
[2]   Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy [J].
Austin, Howard A., III ;
Illei, Gabor G. ;
Braun, Michelle J. ;
Balow, James E. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (04) :901-911
[3]   Nonlupus nephritides in patients with systemic lupus erythematosus: A comprehensive clinicopathologic study and review of the literature [J].
Baranowska-Daca, E ;
Choi, YJ ;
Barrios, R ;
Nassar, G ;
Suki, WN ;
Truong, LD .
HUMAN PATHOLOGY, 2001, 32 (10) :1125-1135
[4]   The very long-term prognosis and complications of lupus nephritis and its treatment [J].
Bono, L ;
Cameron, JS ;
Hicks, JA .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1999, 92 (04) :211-218
[5]   CONTROLLED TRIAL OF PULSE METHYLPREDNISOLONE VERSUS 2 REGIMENS OF PULSE CYCLOPHOSPHAMIDE IN SEVERE LUPUS NEPHRITIS [J].
BOUMPAS, DT ;
AUSTIN, HA ;
VAUGHN, EM ;
KLIPPEL, JH ;
STEINBERG, AD ;
YARBORO, CH ;
BALOW, JE .
LANCET, 1992, 340 (8822) :741-745
[6]   SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL AND IMMUNOLOGICAL PATTERNS OF DISEASE EXPRESSION IN A COHORT OF 1,000 PATIENTS [J].
CERVERA, R ;
KHAMASHTA, MA ;
FONT, J ;
SEBASTIANI, GD ;
GIL, A ;
LAVILLA, P ;
DOMENECH, I ;
AYDINTUG, AO ;
JEDRYKAGORAL, A ;
DERAMON, E ;
GALEAZZI, M ;
HAGA, HJ ;
MATHIEU, A ;
HOUSSIAU, F ;
INGELMO, M ;
HUGHES, GRV ;
CERVERA, R ;
SEBASTIANI, GD ;
FONT, J ;
KHAMASHTA, MA ;
HUGHES, GRV ;
FONT, J ;
CERVERA, R ;
LOPEZSOTO, A ;
VIVANCOS, J ;
INGELMO, M ;
URBANOMARQUEZ, A ;
KHAMASHTA, MA ;
VIANNA, J ;
HUGHES, GRV ;
GIL, A ;
LAVILLA, P ;
PINTADO, V ;
LOPEZDUPLA, M ;
VAZQUEZ, JJ ;
SEBASTIANI, GD ;
DERAMON, E ;
CAMPS, M ;
FRUTOS, MA ;
PERELLO, I ;
SANTOS, PG ;
ABARCA, M ;
NEBRO, AF ;
DOMENECH, I ;
TOKGOZ, G ;
AYDINTUG, AO ;
JEDRYKAGORAL, A ;
MALDYKOWA, H ;
CHWALINSKASADOWSKA, H ;
GALEAZZI, M .
MEDICINE, 1993, 72 (02) :113-124
[7]   Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: The data of the meta-analyses [J].
Chiurchiu, C ;
Remuzzi, G ;
Ruggenenti, P .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 :S58-S63
[8]   Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus [J].
Cooper, Glinda S. ;
Treadwell, Edward L. ;
Clair, E. William St. ;
Gilkeson, Gary S. ;
Dooley, Mary Anne .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (06) :993-999
[9]   PROGNOSTIC DETERMINANTS IN LUPUS NEPHRITIS - A LONG-TERM CLINICOPATHOLOGICAL STUDY [J].
DONADIO, JV ;
HART, GM ;
BERGSTRALH, EJ ;
HOLLEY, KE .
LUPUS, 1995, 4 (02) :109-115
[10]  
Dooley MA, 1997, KIDNEY INT, V11, P88